Literature DB >> 34402263

Research progress on proteasome subunits in regulating occurrence and development of hepatocellular carcinoma.

Jingyi Hu1, Qingqing Wang1, Yang Liu1.   

Abstract

Proteasome is the eukaryotic organelle responsible for degradation of short-lived proteins and involved in maintaining cellular protein homeostasis. It has been reported that during the occurrence and development of hepatocellular carcinoma (HCC), the regulatory particle subunits of proteasome regulate a series of tumor-related proteins, and proliferation, survival-associated signaling molecules, including PTEN gene, P53, Bcl-2, Bcl-2 interacting mediator of cell death (Bim), cyclin-dependent kinase 4(CDK4), transforming growth factor β receptor (TGFBR), E2F1, growth factor receptor-bound protein 2 (GRB2) . Meanwhile, these subunits regulate some tumor-associated pathway protein, such as signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT), inducing their malfunction to promote the occurrence, proliferation, invasion and metastasis of HCC. The core particle subunits are more to perform the degradation of HCC-related proteins, so inhibitors targeting the core particle show a good anti-tumor effect. This review summarizes the current research progress on the regulation and mechanism of proteasome subunits in promoting the occurrence and development .

Entities:  

Keywords:  Hepatocellular carcinoma; Mechanism; Proteasome; Proteasome core particle; Proteasome regulatory particle; Review

Mesh:

Substances:

Year:  2021        PMID: 34402263      PMCID: PMC8710273          DOI: 10.3724/zdxbyxb-2021-0146

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  53 in total

1.  Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.

Authors:  Ruiqi Liu; Yuejin Li; Lantian Tian; Huawen Shi; Jiabei Wang; Yingjian Liang; Boshi Sun; Shuangjia Wang; Meng Zhou; Li Wu; Jianhua Nie; Binlin Lin; Shuli Tang; Yanqiao Zhang; Guangyu Wang; Chunhui Zhang; Jiguang Han; Benjie Xu; Lianxin Liu; Kunmei Gong; Tongsen Zheng
Journal:  Cancer Lett       Date:  2018-11-29       Impact factor: 8.679

2.  PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression.

Authors:  Tao Luo; Jing Fu; An Xu; Bo Su; Yibing Ren; Ning Li; Junjie Zhu; Xiaofang Zhao; Rongyang Dai; Jie Cao; Bibo Wang; Wenhao Qin; Jinhua Jiang; Juan Li; Mengchao Wu; Gensheng Feng; Yao Chen; Hongyang Wang
Journal:  Autophagy       Date:  2015-04-23       Impact factor: 16.016

3.  A Three-Drug Combo for Multiple Myeloma.

Authors: 
Journal:  Cancer Discov       Date:  2016-09-14       Impact factor: 39.397

4.  CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.

Authors:  Chang-Xin Shi; K Martin Kortüm; Yuan Xiao Zhu; Laura A Bruins; Patrick Jedlowski; Patrick G Votruba; Moulun Luo; Robert A Stewart; Jonathan Ahmann; Esteban Braggio; A Keith Stewart
Journal:  Mol Cancer Ther       Date:  2017-09-27       Impact factor: 6.261

5.  Human 20S proteasome activity towards fluorogenic peptides of various chain lengths.

Authors:  Wioletta Rut; Marcin Drag
Journal:  Biol Chem       Date:  2016-09-01       Impact factor: 3.915

Review 6.  Proteasome Structure and Assembly.

Authors:  Lauren Budenholzer; Chin Leng Cheng; Yanjie Li; Mark Hochstrasser
Journal:  J Mol Biol       Date:  2017-06-03       Impact factor: 5.469

7.  Proteomic-based analysis for identification of proteins involved in 5-fluorouracil resistance in hepatocellular carcinoma.

Authors:  Yi Tan; Shukui Qin; Xin Hou; Xiujuan Qian; Jun Xia; Yumei Li; Rui Wang; Changjie Chen; Qingling Yang; Lucio Miele; Qiong Wu; Zhiwei Wang
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.

Authors:  Daniele Baiz; Gabriele Pozzato; Barbara Dapas; Rossella Farra; Bruna Scaggiante; Mario Grassi; Laura Uxa; Carlo Giansante; Cristina Zennaro; Gianfranco Guarnieri; Gabriele Grassi
Journal:  Biochimie       Date:  2008-11-12       Impact factor: 4.079

9.  POH1 deubiquitylates and stabilizes E2F1 to promote tumour formation.

Authors:  Boshi Wang; Aihui Ma; Li Zhang; Wei-Lin Jin; Yu Qian; Guiqin Xu; Bijun Qiu; Zhaojuan Yang; Yun Liu; Qiang Xia; Yongzhong Liu
Journal:  Nat Commun       Date:  2015-10-29       Impact factor: 14.919

10.  PSMC2 Regulates Cell Cycle Progression Through the p21/Cyclin D1 Pathway and Predicts a Poor Prognosis in Human Hepatocellular Carcinoma.

Authors:  Yiwei Liu; Hairong Chen; Xiangcheng Li; Feng Zhang; Lianbao Kong; Xuehao Wang; Jin Bai; Xiaofeng Wu
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.